Multicenter phase II study evaluating Dxl/Cis as induction regimen prior to surgery or radiochemotherapy in stage II-IIIB NSCLC patients (TAX-AT 1.203)

Objectives: Neoadjuvant therapy with a platinum based doublet is an option in NSCLC with upfront resectable disease. However, the role of neoadjuvant induction in stages IIIA and IIIB and in initially not resectable patients is unclear. Patients and Methods: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. Definitive radiochemotherapy (RCT) using weekly docetaxel was the prespecified alternative if patients were not r…